参附益肾胶囊治疗高海拔地区糖尿病肾病的临床观察
Observation of the clinical efficacy of Shenfuyishen Capsule in the treatment of diabetic nephropathy in high altitude regions

摘要：目的 观察参附益肾胶囊治疗高海拔地区阳虚血瘀型糖尿病性肾病的临床疗效。方法 将53例患者随机分为2组，治疗组31例，对照组22例。对照组西医常规治疗；治疗组在对照组基础上给予参附益肾胶囊，观察两组的临床疗效及患者血生化改变情况，如血肌酐(creatinine, SCr)、谷氨酸转氨酶(alanine aminotransferase, ALT)、血尿酸(uric acid, UA)、尿微量蛋白(urinary microalbumin, MALB)、肾小球滤过率(glomerular filtration rate, GFR)等指标。结果 治疗组总有效率90.32%，对照组81.82%，两组比较，有显著性差异(P<0.05)。两组治疗后主要症状均有不同程度改善，与治疗前比较，有显著性差异(P<0.05)。治疗组治疗前后ALT无差异，治疗前后两组的CR、UA、MALB、GFR有差异，且治疗组改善更为显著，与对照组比较，有显著性差异(P<0.05)。 结论 参附益肾胶囊具有改善主要临床症状，降低糖尿病肾病患者CR、GFR、UA、MALB水平，从而保护肾功能，延缓糖尿病性肾病进程的作用。
ABSTACT: Objective To observe the clinical efficacy of Shenfuyishen Capsule in the treatment of diabetic nephropathy of yangxuxueyu type in high- altitude regions. Methods We divided 53 patients randomly into two groups: 31 in the observation group and 22 in the control group. Patients in the control group were treated with conventional regime of Western Medicine. Those in treatment group were given extra treatment with Shenfuyishen Capsule. Then we tested serum creatinine (Scr), uric acid (UA), urinary microalbumin (MALB) and GFR. Results The total efficiency was 90.32% and 81.82% in the treatment group and the control group, which was significantly different (P<0.05). Major symptoms improved after treatment in both groups, which differed significantly compared with those before treatment (P<0.05). ALT in the treatment group was not different after treatment. CR, UA, MALB and GFR significantly differed before and after treatment in both groups, especially in the treatment group (P<0.05). Conclusion Shenfuyishen Capsule helps improve major clinical symptoms and decrease CR, GFR, UA and MLAB levels in patients with diabetic nephrology, thus protecting renal function and delaying the process of diabetic nephropathy